INTRODUCTION

Growth differentiation factor 15 (GDF15) is a member of the transforming growth factor β (TGF-β) superfamily of proteins. Although GDF15 is well established as a potent neurotrophic factor for neurons, little is known about its role in glial cells under neuro pathological conditions. We monitored GDF15 expression in astrocyte activation after a kainic acid (KA)-induced neuro degeneration in the ICR mice hippocampus. In control, GDF15 immunoreactivity (IR) was evident in the neuronal layer of the hippocampus; however, GDF15 expression had increased in activated astrocytes throughout the hippocampal region at day 3 after the treatment with KA. LPS treatment in astrocytes dramatically increased GDF15 expression in primary astrocytes. In addition, LPS treatment resulted in the decrease of the IkB-α degradation and increase of the phosphorylation level of RelA/p65. These results indicate that GDF15 has a potential link to NF-kB activation, making GDF15 a valuable target for modulating inflammatory conditions.

Key words: GDF15, Astrocyte, Excitotoxicity, NF kappaB signaling

Growth differentiation factor 15 (GDF15) is a member of the transforming growth factor β (TGF-β) superfamily of proteins. GDF15 was cloned independently in different laboratories and is therefore known by different names, such as the macrophage inhibitory cytokine-1 (MIC-1) and, nonsteroidal anti-inflammatory drugs (NSAID) activated gene (NAG-1) [1, 2]. Research has shown that GDF15 is widely distributed in the central nervous system (CNS) and the peripheral nervous system (PNS) [3]. Low levels of GDF15 are found in all regions of the unlesioned rat and mouse CNS, such as the peripheral nerves, isolated astrocytes, and the dorsal root ganglion cells (DRGs) [4]. GDF15 is a well established and potent neurotrophic factor for dopamingeric neurons [5], cerebellar granular neurons [6], sensory sympathetic neurons, and spinal cord motor neurons [7]. In a cold-induced injury lesion of the cerebral cortex, GDF15 was found to be highly upregulated in regions adjacent to the lesion site [3]. A similar pattern of GDF15 induction was observed in a mouse model of cerebral ischemia [8]. Although GDF15
expression levels in unlesioned neurons and glia are found to be lower. GDF15 is robustly induced in the lesioned neuron and glia, suggesting that the factor may play a role in the lesioned CNS; however, whether GDF15 plays a similar role in astrocytes has not been precisely defined.

Astrocytes play an important role as the essential mediators of the brain’s innate immune response to a variety of brain insults. During brain injuries, astrocytes secrete proinflammatory cytokines and express key immune receptors, such as TLRs enabling them to mount a proinflammatory response to a number of signals [9, 10]. In addition, astrocytes upregulate the cytoskeletal protein, Glial fibrillary acidic protein (GFAP) and form a physical barrier from infiltrating immune cells in injured brain [11]. Although astrocytes play a critical part in protecting the brain from the inflammatory response, how they respond to anti-inflammatory cytokines and their role in dampening neuroinflammation remains to be determined.

Because Kainic acid (KA) is a glutamate receptor agonist that induces significant excitotoxicity in the hippocampus, an injection of KA results in the hippocampal neuronal cell death and glial activation [12, 13]. Therefore, KA-induced brain damage may provide a suitable model for evaluating the role of GDF15 in reactive gliosis during neuroinflammation. In addition, the upregulation of transcription factors, such as NFκB in astrocytes, induce the expression of neuroprotective molecules [14]. Collectively, this study examined the expression of GDF15 in astrocytes after a KA-induction of an excitotoxic lesion in the mouse hippocampus, and the effect of GDF15 on NFκB signaling in primary astrocytes.

MATERIALS AND METHODS

Experimental Animals and Lesions

Male imprinting control region (ICR) mice (Samtako, Korea) weighing 23–25 g were used in this study. All animal-related procedures were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Chungnam National University (CNU-00151). KA (Sigma, MO, USA) was prepared as a stock solution at 5 mg/ml in sterile 0.1 M PBS; aliquots were stored at –20°C until required. Briefly, KA was injected at right lateral cerebral ventricle (anteroposterior, –0.4 mm; mediolateral, 1 mm; dorsoventral, –2.3 mm relative to bregma) using a 50-µl Hamilton microsyringe fitted with a 26-gauge needle inserted to a depth of 2.4 mm (0.1 µg/5 µl in PBS, i.c.v.). Control mice received an equal volume of saline. KA-injected animals (n=6–8 per group) and saline-injected control animals (n=6/group) were allocated. At 1, 3, and 7 days after KA or saline injection, mice were anesthetized with sodium pentobarbital (50 mg/kg i.p.), and perfused transcardially with heparinized PBS, followed by perfusion with 4% paraformaldehyde in PBS. Their brains were removed, immersed in the same fixative for 4 h, and then cryoprotected in a 30% sucrose solution. They were embedded in tissue freezing medium and then frozen rapidly in 2-methyl butane precooled to its freezing point with liquid nitrogen. Frozen coronal sections (40 µl thick) were obtained using a Leica cryostat.

Immunohistochemistry and Double Immunofluorescence

Parallel free-floating sections were subjected to endogenous peroxidase blocking with 1% H₂O₂ in PBS, followed by treatment with blocking buffer (1% fetal bovine serum [FBS] in PBS and 0.3% Triton X-100 for 30 min) and incubation with primary anti-GDF15 (1:100, #E2430, Spring bioscience) overnight. Immunohistochemical staining of the tissue sections were performed using the avidin–biotin peroxidase complex (ABC) method described previously [15, 16]. In order to simultaneously demonstrate a pair of antigens, in the same section, goat GDF15 was used with glial fibrillary acidic protein (GFAP, 1:1000, #AM020, Biogenex). Free-floating sections were immunoreacted for GDF15 and Cy³-conjugated anti-goat secondary antibody. Sections were then further processed for GFAP and Cy²-conjugated anti-mouse secondary antibody. Nucleus staining was performed with DAPI. Double-stained sections were analyzed with Zeiss Axioshot microscope.

Primary Astrocyte Culture

Rat primary cerebral astrocytes were purified from neonatal rats according to standard procedures [15]. Briefly, a postnatal day 1 (P1) Sprague-Dawley rat pup (Samtako, Korea) was decapitated in an ice-chilled dish and the brain was removed. After removal of the meninges the cerebral cortex was dissected and dissociated in Hanks’ balanced salt solution (HBSS; Invitrogen) supplemented with 5.5 mM glucose, 20.4 mM sucrose, and 4.2 mM sodium bicarbonate. After centrifugation, the cells were seeded into poly-L-lysine-coated T75 flasks and maintained in Minimal Essential Medium (MEM) containing 20% fetal bovine serum (FBS), 100 µM non-essential amino acid solution, 2 mM L-glutamine, and antibiotics. After 7 days, the flasks were agitated on an orbital shaker for 12 h at 200 rpm at 37°C, and the non-adherent oligodendrocytes and microglial cells were removed. The flasks were then trypsinized and expanded in Dulbecco’s Modified Eagle Medium (DMEM) growth media containing 10% FBS, 2 mM L-glutamine, and 1 mM sodium pyruvate. Under these conditions, the purity of the astrocyte population
was 95% as determined by Immunofluorescence analysis using anti-OX-42 to detect microglial cells, anti-CNPase to detect oligodendrocyte contamination, and GFAP to identify astrocytes. For lipopolysaccharide (LPS) treatment, primary astrocytes were trypsinized and seeded in a 60-mm dish at 70% confluence. Cell lysates were processed for immunoblot analysis for indicated times after LPS treatment.

Western Blotting
For western blot, the cells were incubated for 24 h prior to 4 h serum-starvation and stimulated with LPS (100 ng/mL) for the indicated times. Cultured astrocytes were collected by scraping, and the pellet was solubilized in lysis buffer using PRO-PREP reagent (Intron Biotechnology, Sungnam, Korea) with a protease inhibitor cocktail (Sigma P5726). Following normalization of protein content in each sample, 30 µg of the total cellular fraction of each sample was separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transblotted onto nitrocellulose membranes. The blot was probed with primary antibodies, e.g. GDF15, P-p65 (Cell Signaling, #3033S), IκB-α (Santa Cruz, #sc-371), beta-actin (T308, #2965, Cell Signaling, CA, USA) in blocking solution. Membranes were washed for 3 times for 10 min in TBST, and incubated for 1 h with peroxidase labeled secondary antibody (Vector) diluted 1:2000 in TBST. After three further washes, immunolabeled proteins were detected by chemiluminescence using a Supern signal ECL kit (Pierce Chemical) and Biomax Light-1 films (Kodak, USA).

RESULTS

Enhancement of GDF15 expression in Astrocytes Following KA-Induced Excitotoxicity
The intracerebroventricular injection of KA is a well established excitotoxicity model that promotes seizures in mice and selective hippocampal cell death [17, 18]. Previously, we showed a time-dependent pyramidal cell loss and glial activation in this ICR mice model as measured by cresyl violet staining [15]. In this study, a typical loss of pyramidal neurons in the CA3 regions of the ipsilateral hippocampus was apparent on day 1 post-injection of KA. Moreover, glial activation had increased in the hippocampus from day 1 to day 3 (Fig. 1A). To evaluate the involvement of GDF15 in KA-induced excitotoxicity, we measured GDF15 expression in the ipsilateral hippocampus of KA-treated mice. GDF15 immunoreactivity (IR) was evident in the neuronal layer of the hippocampus, including the CA1, CA3, and the dentate gyrus in the control mice (Fig. 1B); however, GDF15 IR in the small nuclei was increased markedly throughout the CA3 region on day 3 post-treatment with KA (Fig. 1Bc, g). To further confirm the cell type in which GDF15 was found, we employed double staining with the anti-GDF15 and anti-GFAP (astrocytic marker) primary antibodies. GDF15 was found to be localized to astrocytic nuclei, indicating that GDF15 expression increased in the activated...
astrocytes in the hippocampi of KA-treated mice (Fig. 2).

**GDF15 is associated with NF-κB activity in Astrocytes Activation**

Because it has been well established that NF-κB plays an essential role in the LPS-induced expression of proinflammatory mediators such as CCL2 and, CXCL2 in astrocytes [19-21], we next examined whether GDF15 influences LPS-induced NF-κB activity in these cells. Consistently, LPS treatment in astrocytes dramatically increased GDF15 expression in a time-dependent manner (Fig. 3, upper panel). To determine the molecular mechanism involved in the NF-κB signaling pathway, we examined the degradation of IκB-α and the phosphorylation of RelA/p65 in LPS-stimulated astrocytes. When the astrocytes were treated with LPS, the phosphorylation level of RelA/p65 began to increase at 1 h after the treatment, and continued to increase for 4 h. LPS treatment also resulted in the decrease of the IκB-α degradation (Fig. 3, middle and lower panel). These results suggest that GDF15 play an important role in NF-κB activity during astrocyte activation induced by LPS.

**DISCUSSION**

We have shown that GDF15 expression increased in the activated astrocytes in the hippocampi of KA-treated mice. Previously, GDF15 expression was investigated in several CNS lesions. In a cold-induced lesion of the cerebral cortex, GDF-15 mRNA was found to be highly upregulated in the majority of lesioned neurons, a minority of microglial cells, and not at all in the astroglial cells [3]. Unsicker groups indicate that GDF-15 IR, while hardly detectable in unlesioned brain areas, was prominently upregulated in neurons, such as neurons within the hippocampus, and while moderate numbers of microglial cells were also stained, astrocytes were consistently GDF15 negative [4]. They also note that GDF15 is robustly induced in lesioned neurons and scattered microglia, and can be visualized by in situ hybridization and immunocytochemistry; however, they observed that astrocytes in the unlesioned and lesioned CNS are devoid of GDF15, in contrast to cultured astrocytes [4, 5]. Conversely, Schwann cells seem to be the most prominent source for GDF15 in the PNS [7]. Studies also show that GDF15 expression in glioblastoma cell lines was significantly lower than that in benign glioma cells and normal human astrocytes [22]. The discrepancy between previous finding on GDF15 expression and our results may be due to the sensitivity of the primary antibody. Unsicker groups mention that GDF15 is hardly detectable in unlesioned brain areas. However, we demonstrate that GDF15 IR was evident in the neuronal layer of the hippocampus, including the CA1, CA3, and the dentate gyrus of the control mice.

TGF-β signaling in astrocytes is highlighted because TGF-β is a master regulatory and primarily anti-inflammatory cytokine that is universally increased during CNS injury [23, 24]. Astrocytic TGF-β signaling limits the inflammation and reduces neuronal damage in CNS toxoplasma infection [25]. In addition, astrocytic TGF-β signaling after stroke decreases subacute neuroinflammation and preserves neuronal function [26]. This emerging evidence suggests that astrocytic TGF-β signaling may be a key pathway for limiting brain inflammation during CNS infection and injury. Astrocytes respond to CNS injury by producing proinflammatory cytokines
and chemokines. For example, astrocytes produce the chemokines CCL2, CXCL1 and CXCL2 after ischemia or spinal cord injury [27, 28], and CCL2 and CCL5 after traumatic brain injury [29]. These pro-inflammatory chemokines may play a beneficial role by attracting the immune cells, which have been shown to reduce tissue damage by clearing dead cells debris [30]. In contrast, excessive inflammation can be harmful by inducing free-radical damage to the neurons [31] and increasing cerebral edema, which can cause brain herniation and further tissue damage [32].

Cell death resulting from excitotoxicity has been associated with different brain disorders implicating an inflammatory response in affected regions [33, 34]. Glial cells, as mediators of the inflammatory response, also have an important role in the course of kainic acid (KA)-induced hippocampal neurodegeneration. To mimic the inflammatory response after KA treated hippocampal neuronal death, we used LPS for in vitro study. In this study, we examined the effect of GDF15, one of the diverse members of the TGF-β superfamily, on the activity of NF-κB, since it has been well established that NF-κB plays an essential role for the expression of proinflammatory mediators such as CCL2, CXCL2 induced by LPS in astrocytes [19-21]. Our results are consistent with the model in which astrocytes use TGFβ signaling to upregulate TGFβ1 and its activator thrombospondin-1 in the peri-infarct cortex during the subacute time window after stroke [26]. We found that astrocytic GDF15 signaling is associated with NF-κB activity in KA-induced neuroinflammation in astrocytes, but found no evidence that it affects pro- or anti-inflammatory cytokine release in these cells. Additionally, it remains with open question whether upregulation of GDF15 in astrocytes modulated immune cell polarization around the injury site, thus exhibiting a neuroprotective function. Because TGFβ is universally upregulated in brain injury, it may represent a common pathway that mediates the endogenous immunoregulatory functions of astrocytes. The anti-inflammatory and neuroprotective functions of astrocytic TGFβ signaling may therefore encompass interactions with other glial cells, such as the microglia, and finally extend their protective effects to the neuron.

ACKNOWLEDGEMENT

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013R1A1A1A05006966) and in part by research fund of Chungnam National University (2014).

REFERENCES

that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J Neurosci 33:12870-86.